Treating major depression is a medical need that remains unmet by monoaminergic
therapeutic strategies that commonly fail to achieve symptom remission. A breakthrough in …

Background The evidence on selective serotonin reuptake inhibitors (SSRIs) for major
depressive disorder is unclear. Methods Our objective was to conduct a systematic review …

Objective: In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces
opioid system activation. The objective of this study was to determine whether opioid …

The goal of this guideline1 is to improve the quality of care and treatment outcomes for
patients with alcohol use disorder (AUD), as defined by DSM-5 (American Psychiatric …

Women with alcohol use disorder (AUD) experience more barriers to AUD treatment and are
less likely to access treatment than men with AUD. A literature review identified several …

Background Alcohol dependence is a major public health problem characterized by
recidivism, and medical and psychosocial complications. The co‐occurrence of major …

Background In patients with an alcohol use disorder, depression is commonly categorised
as independent (ID) or substance-induced (SID). It is not established whether these …

These practice guidelines for the biological treatment of alcohol use disorders are an update
of the first edition, published in 2008, which was developed by an international Task Force of …

Over the past six decades, the use of ketamine has evolved from an anesthetic and
recreational drug to the first non-monoaminergic antidepressant approved for treatment …

Objectif: La comorbidité de la dépendance est un important problème clinique dans les
troubles de l'humeur, mais la meilleure façon de traiter les personnes souffrant de troubles …